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Background. Metabolic syndrome (MS) and sleep-disordered breathing (SDB) are highly prevalent in patients with diabetes
mellitus type 2 (DM2). The present study examined whether there is an independent association between SDB and MS in a
sample of outpatients with DM2. Methods. MS was determined in 679 patients of the DIACORE-SDB substudy, a study of
outpatients with DM2. According to the National Cholesterol Education Program (NCEP) criteria, MS is deﬁned by at least
three of the following ﬁve criteria: waist circumference of >102 cm (men)/>88 cm (women), blood pressure of ≥130/85mmHg, a
fasting triglyceride level of >150mg/dl, high-density lipoprotein (HDL) of <40mg/dl (men)/<50mg/dl (women), and a fasting
glucose level of ≥110mg/dl. The apnea-hypopnea index (AHI) was assessed with a 2-channel ambulatory monitoring device and
used to deﬁne the severity of SDB (AHI < 15 0: no/mild SDB; AHI 15.0-29.9: moderate SDB; AHI ≥ 30 0: severe SDB). Results.
228 (34%) of the 679 participants (mean age 66 years, mean body mass index (BMI) 31.2 kg/m2, and mean AHI 14/hour) had
SDB. MS was signiﬁcantly more frequent in patients with more severe SDB (no/mild SDB vs. moderate SDB vs. severe SDB:
72% vs. 79% vs. 85%, respectively, p = 0 038). Logistic regression analysis adjusted for sex, age, obesity (BMI ≥ 30 kg/m2), and
the HOMA index showed a signiﬁcant association between the AHI and the presence of MS (OR 95%CI = 1 039 (1.011;
1.068); p = 0 007). Further, male sex, obesity, and the HOMA index were signiﬁcantly associated with MS. Conclusion. SDB is
signiﬁcantly and independently associated with MS in outpatients with DM2.
1. Introduction
The most common type of sleep-disordered breathing (SDB)
is obstructive sleep apnea (OSA) [1]. OSA is characterised by
recurrent collapse of the upper airway during sleep leading
to oxygen desaturation with consecutive arousals from sleep
[2, 3]. The pattern of desaturation and reoxygenation results
in intermittent hypoxia, which is the main reason for meta-
bolic dysfunction in SDB and is associated with the compo-
nents of metabolic syndrome, which means hypertension,
visceral obesity, pathological glucose tolerance, and dyslipi-
daemia [4–7]. The pathological mechanisms of SDB that
cause hypertension include baroreﬂex impairment as well
as hypoxia-induced activation of chemoreﬂex sensors, which
increase both the sympathetic tone and peripheral vascular
resistance [8–10]. Endothelial dysfunction due to hypoxia
and oxidative stress also contribute to cardiovascular disease
and hypertension [11]. Obesity is strongly associated with
OSA in a bidirectional manner: visceral obesity is a risk factor
of OSA [12–14]. The accumulation of visceral fat reduces
lung volume and thoracic compliance, thus generating
negative thoracic pressure, which subsequently leads to pha-
ryngeal occlusion [14]. In addition, the deposition of adipose
tissue in the upper airway facilitates collapsibility by narrow-
ing pharyngeal patency [15]. At the same time, OSA leads to
weight gain mostly due to endocrine dysregulation and phys-
ical inactivity because of daytime sleepiness [13, 16–18].
Endocrine alterations and fragmentation of sleep are also
involved in impaired glucose metabolism, leading to patho-
logical glucose tolerance and insulin resistance [19–21].
Thus, SDB increases the risk of developing DM2 [1, 22].
The association between SDB and dyslipidaemia, deﬁned as
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an increase in triglyceride and a decrease in HDL levels,
also contributes to intermittent hypoxia [23]. Treatment
of SDB includes weight loss as well as therapy with con-
tinuous positive airway pressure (CPAP), which lowers
blood pressure and improves glucose metabolism as well
as the lipid proﬁle [1, 10, 13, 22, 24, 25].
Overall, MS is strongly associated with SDB, and the
reported prevalence ranges from 23% to 87% [5]. The present
study examined whether there is an independent association
between SDB and MS in a sample of outpatients with DM2.
2. Material and Methods
2.1. Study Design. The examined patients were participants of
the DIACORE- (DIAbetes COhoRtE-) SDB substudy, a
prospectively designed study of patients with DM2. Major
diabetologists and medical insurance companies invited
outpatients with DM2 in written form to participate in
the study. Patients previously treated at the Department
of Internal Medicine of the University Hospital Regens-
burg were also invited [26]. The diabetic status was deter-
mined by assessing diabetes medication or by validating
self-report. Patients underwent a standardized physical
examination and biosampling and had to ﬁll in an online
questionnaire [26]. Of 1036 individuals invited to partici-
pate in the DIACORE-SDB substudy, 721 agreed and were
tested with a two-channel respiratory monitor (Apnea-
Link®, ResMed) [27]. Complete SDB parameters were
recorded for 679 patients (94% of the 721 tested). MS
could not be determined in two patients because of missing
data on waist circumference and the triglyceride level. Thus,
677 participants were analysed with regard to the presence of
MS. Follow-up is currently ongoing, so that the cross-
sectional baseline data was used for the present investigation.
The protocol, the data protection strategy, and the study
procedures were approved by the Ethics Committees of the
participating institutes and were in accordance with the Dec-
laration of Helsinki. Patients participated in the DIACORE
study only after providing informed written consent.
2.2. Study Population. All DM2 outpatients living in the city
and district of Regensburg were eligible for participating in
the DIACORE-SDB substudy. Further inclusion criteria
were the ability to fully understand the study information,
to provide written informed consent, age ≥ 18 years, and
self-reported Caucasian ethnicity [26]. Exclusion criteria
were chronic renal replacement therapy (haemodialysis, peri-
toneal dialysis, or transplantation), history of active malig-
nancy within the past ﬁve years, presence of an autoimmune
disease potentially aﬀecting kidney function, haemochroma-
tosis, known pancreoprivic or self-reported type 1 diabetes
mellitus, acute infection, fever, pregnancy, chronic viral hep-
atitis, and HIV infection [26]. Patients were included in the
DIACORE-SDB substudy if they consented to undergo SDB
screening and excluded if they currently used positive airway
pressure therapy [27].
2.3. Assessment of SDB. SDB was assessed with the portable
ApneaLink device (ResMed, Sydney, Australia) consisting
of a nasal cannula and an oxygen clip to measure nasal ﬂow
and pulse oximetry. Trained study personnel instructed the
participants on how to use the device at home. Several
studies have validated the ApneaLink device (ResMed,
Sydney, Australia) for the screening of SDB [28, 29]. The
AHI, oxygen desaturation index, mean oxygen saturation,
and minimum SpO2 were assessed. The default settings
of the screening device were used for the deﬁnitions of
apnea, hypopnea, and desaturation: apnea was deﬁned as
a ≥80% decrease in airﬂow for ≥10 seconds, hypopnea as
a decrease in airﬂow by ≥50-80% versus baseline for ≥10
seconds, and desaturation as a ≥4% decrease in oxygen
saturation [27]. The cut-oﬀ for the diagnosis of SDB was
an AHI ≥ 15/h. Patients with an AHI < 15/h were assumed
to have no or mild SDB. An AHI ≥ 15 up to 29 was
deﬁned as moderate SDB and an AHI ≥ 30 as severe
SDB [24]. A diﬀerentiation between obstructive and central
sleep apnea was not possible because of the absence of a
breast belt. Daytime sleepiness was assessed by means of
the Epworth Sleepiness Scale (ESS), and a score of ≥11 was
considered as excessive daytime sleepiness [30].
2.4. Assessment of Metabolic Syndrome. According to the
NCEP criteria, MS is deﬁned by at least three of the following
ﬁve criteria [4]: visceral obesity, deﬁned by a waist circumfer-
ence of >102 cm in men or > 88 cm in women; dyslipidaemia,
deﬁned by high-density lipoprotein (HDL) of <40mg/dl in
men or < 50mg/dl in women; a fasting triglyceride level of
>150mg/dl or use of triglyceride-lowering medication;
hypertension, deﬁned by blood pressure of ≥130/85mmHg
or use of antihypertensive medication; and presence of a
pathological glucose tolerance with a fasting glucose level of
≥110mg/dl.
Weight in light clothing was measured with a digital
scale. Blood pressure and heart rate were measured with a
vital signs monitor after the patient had been sitting at rest
for at least ﬁve minutes. Waist circumference is deﬁned as
the smallest circumference between the upper iliac crest
and the lower coastal margin. In case of obesity, waist cir-
cumference was measured midway between the upper iliac
crest and lower costal margin. Blood samples (serum gel,
EDTA, and sodium ﬂuoride (Sarstedt, Germany) and PAX-
gene tubes (PreAnalytix GmbH, Switzerland)) were taken
after the patient had been sitting at rest for 15 minutes [26].
2.5. Statistical Analysis. Descriptive data are presented as the
mean (±SD). Normally distributed values of baseline char-
acteristics were evaluated with Student’s unpaired two-
sided t-test. Metabolic parameters were compared with
increasing severity of SDB (no/mild, moderate, and severe)
by one factorial variance analysis (ANOVA) and the post
hoc test (Bonferroni). The inﬂuence of the AHI on the
presence of the metabolic syndrome and its criteria were
assessed with logistic regression models. Known modula-
tors such as age, sex, obesity, and insulin resistance were
included as covariates. Insulin resistance was assessed by
means of the Homeostasis Model Assessment index
(HOMA index) that has been validated in previous studies
[31–33]. Obesity was deﬁned as a body mass index (BMI)
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of ≥30 kg/m2. Results are given as the odds ratio and 95%
conﬁdence interval; p values of <0.05 were considered sig-
niﬁcant. Data were analysed with the SPSS statistical soft-
ware package (SPSS 23.0, IBM SPSS Statistics, Armonk,
New York, USA).
3. Results
3.1. Patient Characteristics. The 679 patients of the SDB sub-
study (Figure 1) had a mean age of 65.6 years, and 61% were
men. Patients were mostly obese (mean BMI 31.2 kg/m2),
and the mean duration of DM2 was 10.2 years. Anamnesis
of medication showed that 81% of participants received anti-
hypertensive medication, 47% cholesterol-lowering agents,
and 85% antidiabetic agents. 27% of patients required insulin
therapy (Table 1).
3.2. Characteristics according to Severity of SDB. Patients
were classiﬁed into three groups according to the severity of
SDB. Of the 228 patients with SDB, 163 had moderate
(AHI ≥ 15/h and <30/h) and 65 severe (AHI ≥ 30/h) SDB.
Baseline characteristics were compared among the three
groups. Patients with SDB were predominantly older, male,
and mostly obese with a signiﬁcantly higher waist circumfer-
ence, higher waist-hip ratio, and higher systolic blood pres-
sure as well as a lower HDL level (Table 2).
3.3. SDB and MS. According to the NCEP criteria, MS was
prevalent in 75% of the participants, and 80% of the patients
with SDB had MS. The comparison of the severity of SDB
among the three groups showed that MS as well as its compo-
nents visceral obesity and hypertension was signiﬁcantly
more frequent in patients with more severe SDB (Figure 1).
The criterion of elevated fasting glucose level was excluded,
because DM2 was prevalent in all participants.
After adjusting for sex, age (in decades), obesity (deﬁned
as BMI ≥ 30 kg/m2), and the HOMA index in a multivariate
regression analysis, the AHI was signiﬁcantly and indepen-
dently associated with the presence of MS (OR (95%
CI) = 1.039 (1.011; 1.068); p = 0 007). Male sex, obesity, and
the HOMA index were independent modulators of MS. In
the same multivariable regression, the AHI was also
Metabolic syndrome
p = 0.038
(ANOVA)
p = 0.012
(ANOVA)
p = 0.014
(ANOVA)
p = 0.363
(ANOVA)
p = 0.681
(ANOVA)
p = 0.079
p = 0.031
p = 0.011
p = 1.000
p = 1.000
72%
79%
85% 89%
94%
99%
60% 61%
#
79%
45%
50% 51%
26% 29%
31%
100%
80%
60%
40%
20%
0%
Blood pressure
≥ 135/85 mmHg⁎
Waist circumference
> 102 cm (m) or >88 cm (f)
Sober triglycerides
> 150 mg/dl⁎⁎
HDL < 40 mg/dl (m) or
<50 mg/dl (f)
No/mild SDB
Moderate SDB
Severe SDB
Figure 1: Prevalence of NCEP criteria (except elevated fasting glucose) in participants with no or mild, moderate, and severe SDB.
Comparison of the prevalence of NCEP criteria with ANOVA and the post hoc test (Bonferroni) between no/mild and severe SDB.
Results are shown with 95% conﬁdence intervals. m: male, f: female; ∗or on antihypertensive medication, ∗∗or on triglyceride-lowering
medication. #Signiﬁcant diﬀerence between moderate and severe SDB (p = 0 041).
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signiﬁcantly associated with several components of MS: ele-
vated waist circumference (OR (95% CI) = 1.031 (1.006;
1.056); p = 0 014), hypertension (OR (95% CI)= 1.049
(1.000; 1.100); p = 0 048), and hypertriglyceridemia (OR
(95% CI) = 1.018 (1.002; 1.035); p = 0 029) (Table 3).
4. Discussion
The present study shows that, in patients with DM2, MS and
its criteria hypertension and visceral obesity were
signiﬁcantly more frequent with increasing severity of
SDB. Logistic regression analysis yielded a signiﬁcant and
independent association between increasing AHI and the
prevalence of MS as well as visceral obesity, hypertension,
and hypertriglyceridemia.
Our data conﬁrm the results of previous studies describ-
ing a higher prevalence of MS in patients with SDB [34–38]
(Table 4). However, the present study complements previous
studies in the following manner.
First, previous studies were not conducted in a sample of
outpatients with DM2. Although some studies included
patients with DM2 or with pathological glucose tolerance,
the percentage is still rather low (5-30%) [5, 34, 37–40]. Thus,
to our knowledge, the present study is the ﬁrst to exclusively
analyse the association of SDB with MS and its components
in patients with DM2.
Second, several previous studies deﬁned SDB as an AHI
≥ 5 or ≥10 [5, 34, 37–41]. However, our participants with
an AHI < 15/h were not sleepy, which was shown by the
low ESS (Table 2); thus, they did not require any treatment.
For this reason, we deﬁned clinically relevant SDB as an
AHI ≥ 15 and used the recommended classiﬁcation of SDB
severity [24].
With respect to the prevalence of MS criteria, our
ﬁndings are mostly consistent with previous study results.
The association of SDB with hypertension [34, 37–40] and
obesity [37, 38], as in the present study, is well known. Nev-
ertheless, Kono et al. and Lin et al. found a signiﬁcant associ-
ation of SDB with the components of MS in nonobese
patients [39, 40]. Parish et al. did not ﬁnd any signiﬁcant dif-
ferences in the BMI between patients with and without OSA
and assessed hypertension as the main factor for MS in
patients with OSA [34]. Although most of our patients were
obese and obesity remains to be signiﬁcantly associated with
MS, we found an independent association of the AHI with
MS in a logistic regression model.
Results concerning an association between SDB and
dyslipidaemia according to NCEP criteria have been incon-
sistent [34, 37, 39]. In the present study, there was no signif-
icant association between SDB and dyslipidaemia. However,
a signiﬁcant association between the severity of SDB and
decreased HDL could be found. Also, other studies which
were calculated with continuous variables of dyslipidaemia
instead of NCEP criteria showed an association between
SDB and the lipid proﬁle, such as elevated triglycerides and
low HDL [35–39, 42–44].
SDB is associated with pathological glucose tolerance and
insulin resistance [19, 20]. In the present study, the duration
of DM2 was signiﬁcantly longer in patients with SDB than in
patients with no or mild SDB (11 4 ± 9 0 vs. 9 5 ± 7 4 years;
p = 0 005).
With respect to the association of SDB and components
of MS, Coughlin et al. discussed in their review whether
SDB may be a component of MS [45]. When examining
patients of the Wisconsin Sleep Cohort Study for metabolic
parameters, Nieto et al. [41]. detected a signiﬁcant associa-
tion of SDB with MS independent of sex, age, BMI, sympa-
thetic, and neuroendocrine parameters; thus, the authors
considered SDB (deﬁned as an AHI ≥ 5) to be a component
Table 1: Baseline characteristics.
N = 679
Age (years) 65 6 ± 8 8
Sex, male (n (%)) 412 (60.7%)
AHI/h 14 ± 13
Metabolic parameters
Waist circumference (cm) 100 8 ± 16 6
BMI (kg/m2) 31 2 ± 5 5
Systolic BP (mmHg) 138 ± 18
Diastolic BP (mmHg) 75 ± 10
HDL (mg/dl) 52 8 ± 14 9
Triglycerides (mg/dl) 171 4 ± 131 5
Duration of DM2 (years) 10 2 ± 8 0
HbA1c (%) 6 8 ± 1 1
(mmol/mol) 51 ± 12
HOMA index∗ 6 2 ± 7 5
Medication N (%)
Antihypertensive medication
Antihypertensive medication altogether 547 (81%)
ACE inhibitor 280 (41%)
Angiotensin receptor blocker 164 (24%)
Renin inhibitor 3 (<1%)
Calcium channel blocker 191 (28%)
Beta-blocker 322 (47%)
Diuretics 267 (39%)
Fat metabolism
HMG-CoA-reductase inhibitor 318 (47%)
Diabetes medication
Antidiabetic agents altogether 575 (85%)
Biguanide 459 (68%)
Incretin 153 (23%)
Sulfonylurea 127 (19%)
Glinide 26 (4%)
Alpha-glucosidase inhibitor 9 (1%)
Exenatide 6 (1%)
Insulin 181 (27%)
Results are provided as mean ± standard deviation or n (%). AHI: apnea-
hypopnea index; BMI: body mass index; BP: blood pressure; HbA1c:
haemoglobin A1c; HOMA: Homeostasis Model Assessment (fasting, use of
long-acting insulin); DM2: diabetes mellitus type 2; HDL: high-density
lipoprotein; ∗413 patients included.
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of MS [41]. The present study also showed an increasing risk
of MS as well as of visceral obesity, hypertension, and
hypertriglyceridemia with a rising AHI. However, using a
high cut-oﬀ and deﬁning SDB as an AHI ≥ 15, the prevalence
of SDB in patients with MS was rather low (36%) compared
to the prevalence of hypertension (97%), visceral obesity
(80%), and hypertriglyceridemia (61%) in patients with MS;
therefore, there is no suﬃcient evidence to substantiate the
claim that SDB is an integral component of MS.
The strength of our study is its large sample size with
central data management and standardized protocols [26].
Furthermore, to our knowledge, this is the ﬁrst study exam-
ining the association between SDB and MS in outpatients
with DM2. There are some limitations that warrant discus-
sion: First, a distinction between central and obstructive sleep
apnea was not possible because of the use of a portable yet
validated and established [28, 29] SDB monitoring device
instead of polysomnography. Second, as our data stem from
a cross-sectional analysis, we were only able to assess an asso-
ciation between SDB and MS but could not prove any causal-
ity. Third, since 100% of participants of the DIACORE-SDB
substudy have diabetes, results cannot be extrapolated to
patients with milder forms of altered glucose metabolism
(fasting glucose < 126 mg/dl).
In summary, our ﬁndings showed that SDB is signiﬁ-
cantly and independently associated with MS in outpa-
tients with DM2. As previous randomized controlled
trials of CPAP treatment in patients with DM2 fell short
of identifying an eﬀect on glucose metabolism [46], future
large-scaled long-term interventional studies are required.
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